Jim Cramer: Sell Insys Therapeutics, Invensense, and These 2 Stocks

Jim Cramer made the following calls on October 10th, 2013. What do you think about his picks?

Insys Therapeutics (NASDAQ:INSY): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Buy on October 1, 2013. The stock’s 52-week high is $53.64, and its 52-week low is $6.55. Cramer said that it was time to gt out of Insys Therapeutics, a stock that a prudent investor could have mad nearly a 500 percent return on. Cramer pointed to other pharmaceutical companies that have seen fantastic price drops amid FDA news as a reminded of what could go wrong in the sector at any point in time.

INSY-20131011

InvenSense Inc (NYSE:INVN): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Sell on November 16, 2012. The stock’s 52-week high is $20.15, and its 52-week low is $9.09. Cramer was not a fan of the motion processing company. He said that, while he does like the stock to a certain degree, there are better picks out there, especially given uncertainty in the markets surrounding the government shutdown.

INVN-20131011

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Buy on October 1, 2013. The stock’s 52-week high is $39.83, and its 52-week low is $7.56. Cramer said that it was time to get out of Isis Pharmaceuticals, taking any possible profits home to the bank. Cramer mentioned that the share prices for many pharmaceutical companies currently reflect a large share of the potential upside of the stocks without factoring in the downside, part of the rationale for his sell ranking on Isis.

ISIS-20131011

Lannett Co Inc (AMEX:LCI): Jim Cramer ranked this stock a Sell. The stock’s 52-week high is $23.42, and its 52-week low is $3.93. Cramer was not a fan of the generic pharmaceutical company, saying that there were better picks in the sector at the current point in time.

LCI-20131011

Don’t Miss: IMF: Debt Levels Across the Globe Appear Stable.

More from The Cheat Sheet